Wedbush Cuts Artiva Biotherapeutics to Neutral, Lowers Target to $4
Wedbush lowered its rating from Outperform and cut its price target to $4 from $40.
Related stories
L3Harris Reports Third-Quarter Revenue of $6.06 Billion
M impact | EQUITY | Oct 29, 2026, 10:13 AM UTC
L3Harris Reports Strong Third-Quarter Results and Record Backlog
L3Harris Technologies reported its third-quarter 2026 results and said backlog reached record levels.
M impact | EQUITY | Oct 29, 2026, 10:12 AM UTC
Pediatrix Medical Reports Third-Quarter Revenue of $501.4 Million
M impact | EQUITY | Oct 29, 2026, 10:01 AM UTC
CRH Reports Third-Quarter Revenue of $11.4B
M impact | EQUITY | Oct 29, 2026, 10:00 AM UTC
Bunge Reports Third-Quarter 2026 Results
M impact | EQUITY | Oct 29, 2026, 10:00 AM UTC
KBR Reports Third-Quarter Revenue of $2.03 Billion
M impact | EQUITY | Oct 29, 2026, 10:00 AM UTC